0001733413
false
0001733413
2023-11-14
2023-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 14, 2023
TFF
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware |
|
001-39102 |
|
82-4344737 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification Number) |
1751
River Run, Suite 400
Fort
Worth, Texas
76107
|
(Address
of principal executive offices) |
(817)
438-6168 |
(Registrant’s
telephone number, including area code) |
(Former
name or former address, if changed since last report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions.
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Securities
registered pursuant to Section 12(b)of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock: Par value $.001
|
|
TFFP
|
|
Nasdaq
Capital Market
|
Item 2.02
Results of Operations and Financial Condition.
On
November 14, 2023, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for
the fiscal quarter ended September 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated
herein by reference.
The
information in this Item 2.02, including the press release attached as Exhibit 99.1 hereto, is furnished pursuant to Item 2.02
but shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it
be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01
Financial Statements and Exhibits
(d) |
Exhibits |
Method Filing |
The following
exhibit is furnished with this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
TFF
PHARMACEUTICALS, INC. |
|
|
Dated:
November 14, 2023 |
/s/
Kirk Coleman |
|
Kirk
Coleman, |
|
Chief
Financial Officer |
2
Exhibit 99.1
TFF
Pharmaceuticals Reports
Third
Quarter 2023 Financial Results
and
Provides Corporate Update
Company
remains on track to report initial data from TFF VORI and TFF TAC Phase 2 trials by the end of 2023
Conference call and webcast, today Tuesday November 14, 2023, at 4:30 pm
ET, to provide overview of expected data readouts from Phase 2 studies
FORT WORTH, TX – Nov 14, 2023 – TFF Pharmaceuticals,
Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing
innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the
third quarter of 2023 and provided a corporate update.
“Based on the considerable progress that
we have achieved over the last several months, we continue to expect initial data from our ongoing Phase 2 trials of TFF VORI and TFF
TAC by year-end,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. “TFF VORI and TFF TAC have been
designed to address the significant unmet needs in two rare disease indications, each with high mortality rates in patient populations
with very few treatment alternatives. We therefore expect these initial Phase 2 data will provide meaningful clinical insights on each
drug’s safety, tolerability and efficacy to help guide our clinical development strategy as we enter into 2024.”
Recent Clinical and Corporate Highlights:
In November 2023, the Company announced the publication of
research demonstrating the feasibility of intranasal delivery of monoclonal antibodies (mAbs) using the Company’s proprietary Thin
Film Freezing technology. The paper, entitled “Feasibility of Intranasal Delivery of Thin-film Freeze-dried Monoclonal Antibodies”,
was first published on October 24, 2023, by bioRxiv and can be found here.
| ● | In August 2023, the Company announced the closing of a $5.7
million equity financing, including the full exercise of the underwriter’s overallotment option. The financing provided additional
capital to extend the Company’s cash runway into Q22024. |
| ● | In July 2023, the Company and Durbin jointly announced the
opening of an Expanded Access Program (EAP) for TFF VORI, enabling patients access to TFF VORI in the United States, Australia, United
Kingdom, Canada and select countries in Europe. The EAP is meant to provide access to TFF VORI in patients who are not eligible for the
ongoing clinical trial and who have limited or no other treatment options or who have had unfavorable response to adequate standard of
care therapy including to oral or intravenous voriconazole. |
Financial Results
For the quarter ended September 30, 2023, compared to quarter ended
September 30, 2022
| ● | Cash Position: as of September 30, 2023, TFF Pharmaceuticals
reported cash and cash equivalents of $9.7 million. Based on the gross proceeds of 5.7 million dollars received from the financing transaction
that closed on August 17, 2023, the Company expects its current cash runway to fund operations into the second quarter of 2024. |
| ● | Research and Development (R&D) expenses: R&D expenses
for the third quarter of 2023 were $2.4 million, compared to $4.0 million for the comparable period in 2022. The $1.6 million decrease
year-over-year is primarily a result of higher clinical and manufacturing expenses in the prior year period associated with the set-up
of the TFF VORI and TFF TAC Phase 2 clinical trials. |
| ● | General & Administrative (G&A) expenses: G&A
expenses for the third quarter of 2023 were $2.3 million, compared to $3.3 million for the comparable period in 2022. The $1.0 million
decrease year-over-year is primarily related to decreased professional fees and patent expenses, insurance, consulting and market research,
and payroll and related expenses. |
| ● | Net Loss: TFF Pharmaceuticals reported a net loss for the
third quarter of 2023 of $4.4 million, compared to a net loss of $7.3 million for the comparable period in 2022. |
Conference Call and Webcast Information
The Company will host a conference call today, Tuesday,
November 14, 2023, at 4:30 PM Eastern Time, to discuss third quarter 2023 financial results and the corporate update. To participate in
the conference call, please utilize the following information:
Domestic Dial-In Number: Toll-Free: 1-888-886-7786
International Dial-In Number: 1-416-764-8658
Conference ID: 08897681
Call me™: LINK (will be made active 15 minutes prior
to the scheduled start time)
The call will also be broadcast live over the
Web and can be accessed on TFF Pharmaceuticals’ Website, https://tffpharma.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1637201&tp_key=3b92c57ca8
The conference call will also be available for replay for one month on the Company’s website in the Events Calendar of the Investors
section.
ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING (TFF) TECHNOLOGY
TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds
and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is a particle engineering
process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical
and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing
challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy.
The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses
compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders
created by TFF can deliver as much as 75% of the dose to the deep lung. TFF does not introduce heat, shear stress, or other forces that
can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into
easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages
of TFF can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products.
ABOUT TFF PHARMACEUTICALS TFF
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform
medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile TFF technology
platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant
dry powder highly advantageous for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead
drug candidates in the clinic: TFF VORI (Voriconazole Inhalation Powder) and TFF TAC (Tacrolimus Inhalation Powder). The Company continues
collaborations with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare
around the globe. The TFF Platform is protected by over 170 patents issued or pending in the U.S. and internationally. To learn more
about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
SAFE HARBOR This press release contains forward-looking
statements regarding TFF Pharmaceuticals, Inc., including, plans for releasing initial clinical data by the end of 2023, the adequacy
of the Company’s cash runway to meet its near-term funding needs, and the benefits of the Company’s TFF platform. Those forward-looking
statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among
those factors are: (i) the risk that the Company may not be able to release initial clinical data for TFF VORI and TFF TAC by the end
of 2023 or, if it is able to do so, that such clinical data will be positive, (ii) the risk that the Company’s working capital after
giving effect to the recently announced public offering will not be sufficient to fund the Company’s working capital requirements
through Q1 2024, (iii) the risk that the Company’s preclinical and IND enabling studies of the dry powder formulation of the universal
influenza vaccine may not be successful, (iv) the risk that the Company may not be able to successfully conclude clinical testing of its
TFF VORI or TFF TAC or obtain pre-market approval of any of its dry powder product candidates, (v) success in early phases of pre-clinical
and clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily
predict final results, (vi) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated
into a commercial drug product, (vii) the Company has no current agreements or understandings with any large pharmaceutical companies
for the development of a drug product incorporating the TFF Platform, (viii) the risk that the Company will not be able to conclude a
long-term commercial agreement with any third-party, and (ix) those other risks disclosed in the section “Risk Factors” included
in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2023. TFF Pharmaceuticals
cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and
specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they
occur, except as required by law.
Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors
(212) 915-2577
cdavis@lifesciadvisors.com
TFF PHARMACEUTICALS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | |
| | |
| | |
| |
Grant revenue | |
$ | 234,763 | | |
$ | 87,586 | | |
$ | 619,543 | | |
$ | 183,025 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 2,386,707 | | |
| 4,025,940 | | |
| 9,087,264 | | |
| 14,360,293 | |
General and administrative | |
| 2,268,656 | | |
| 3,342,266 | | |
| 8,058,235 | | |
| 10,238,744 | |
Total operating expenses | |
| 4,655,363 | | |
| 7,368,206 | | |
| 17,145,499 | | |
| 24,599,037 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (4,420,600 | ) | |
| (7,280,620 | ) | |
| (16,525,956 | ) | |
| (24,416,012 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 88,810 | | |
| 6,119 | | |
| 160,009 | | |
| 19,184 | |
Change in fair value of note receivable | |
| (77,454 | ) | |
| - | | |
| (114,870 | ) | |
| - | |
Total other income, net | |
| 11,356 | | |
| 6,119 | | |
| 45,139 | | |
| 19,184 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (4,409,244 | ) | |
$ | (7,274,501 | ) | |
$ | (16,480,817 | ) | |
$ | (24,396,828 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (0.09 | ) | |
$ | (0.29 | ) | |
$ | (0.41 | ) | |
$ | (0.96 | ) |
Weighted average common shares outstanding, basic and diluted | |
| 47,441,693 | | |
| 25,451,691 | | |
| 39,983,825 | | |
| 25,399,352 | |
TFF PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
(Unaudited) | | |
| |
| |
| | |
| |
ASSETS | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 9,725,755 | | |
$ | 16,612,315 | |
Research and development tax incentive receivable | |
| 361,485 | | |
| 186,507 | |
Prepaid assets and other current assets | |
| 805,659 | | |
| 2,226,344 | |
Total current assets | |
| 10,892,899 | | |
| 19,025,166 | |
Operating lease right-of-use asset, net | |
| 139,230 | | |
| 196,044 | |
Property and equipment, net | |
| 2,064,354 | | |
| 3,078,342 | |
Note receivable - Augmenta | |
| 1,781,000 | | |
| 1,812,975 | |
Other assets | |
| 7,688 | | |
| 7,688 | |
Total assets | |
$ | 14,885,171 | | |
$ | 24,120,215 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 983,287 | | |
$ | 919,607 | |
Accrued compensation | |
| - | | |
| 4,430 | |
Deferred research grant revenue | |
| 76,000 | | |
| 126,000 | |
Current portion of operating lease liability | |
| 82,725 | | |
| 80,625 | |
Total current liabilities | |
| 1,142,012 | | |
| 1,130,662 | |
Operating lease liability, net of current portion | |
| 52,230 | | |
| 110,094 | |
Total liabilities | |
| 1,194,242 | | |
| 1,240,756 | |
| |
| | | |
| | |
Commitments and contingencies | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Common stock | |
| 59,134 | | |
| 36,193 | |
Additional paid-in capital | |
| 127,404,746 | | |
| 120,070,983 | |
Accumulated other comprehensive loss | |
| (203,712 | ) | |
| (139,295 | ) |
Accumulated deficit | |
| (113,569,239 | ) | |
| (97,088,422 | ) |
Total stockholders’ equity | |
| 13,690,929 | | |
| 22,879,459 | |
Total liabilities and stockholders’ equity | |
$ | 14,885,171 | | |
$ | 24,120,215 | |
5
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024